| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-06 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.22 | 2e-06 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-06 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-06 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.14 | 5e-06 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-06 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.2 | 6e-06 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.17 | 6e-06 |